iVeena Delivery Systems said earlier this month that it finished a pilot trial for its IVMED-10 bioerodible implant designed to treat pain and inflammation after cataract surgery.
Placed during cataract surgery, the sustained-release implant delivers dexamethasone for two weeks from the lens capsule.
The company’s Phase I/IIa trial enrolled eight patients and found that IVMED-10 was safe and effective at controlling the inflammation usually observed after cataract surgery.
iVeena reported that retinal thickness outcomes were comparable to published data for standard of care therapies, like NSAIDs and steroids.
The company added that adverse events, including elevated intraocular pressure and corneal edema, were transient.
“The results of the study are very encouraging,” CEO Jerry Simmons said in prepared remarks. “This study was designed to measure the safety of IVMED-10 and it met the primary objectives. These results support the ongoing clinical development of IVMED-10 and warrant further investigation into the intracapsular platform.”
